155 related articles for article (PubMed ID: 35019216)
1. CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia.
Kurihara Y; Mizuno H; Honda A; Shimura A; Fujioka Y; Maki H; Kurokawa M
J Cell Mol Med; 2022 Feb; 26(3):950-952. PubMed ID: 35019216
[No Abstract] [Full Text] [Related]
2. A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia.
Chung A; Hou Y; Ohgami RS; Von Gehr A; Fisk DG; Roskin KM; Li X; Gojenola L; Bangs CD; Arber DA; Fire AZ; Cherry AM; Zehnder JL; Gotlib J; Merker JD
Cancer Genet; 2017 Oct; 216-217():10-15. PubMed ID: 29025582
[TBL] [Abstract][Full Text] [Related]
3. A
Venable ER; Gagnon MF; Pitel BA; Palmer JM; Peterson JF; Baughn LB; Hoppman NL; Greipp PT; Ketterling RP; Patnaik MS; Kelemen K; Xu X
Cold Spring Harb Mol Case Stud; 2023 Feb; 9(1):. PubMed ID: 36627146
[TBL] [Abstract][Full Text] [Related]
4. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
[TBL] [Abstract][Full Text] [Related]
5. T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.
Schoelinck J; Gervasoni J; Guillermin Y; Beillard E; Pissaloux D; Chassagne-Clement C
Virchows Arch; 2024 May; 484(5):853-857. PubMed ID: 37985498
[TBL] [Abstract][Full Text] [Related]
6. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
Shao H; Wang W; Song J; Tang G; Zhang X; Tang Z; Srivastava J; Shah B; Medeiros LJ; Zhang L
Leuk Res; 2020 Dec; 99():106460. PubMed ID: 33166908
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia.
Jawhar M; Naumann N; Knut M; Score J; Ghazzawi M; Schneider B; Kreuzer KA; Hallek M; Drexler HG; Chacko J; Wallis L; Fabarius A; Metzgeroth G; Hofmann WK; Chase A; Tapper W; Reiter A; Cross NCP
Leukemia; 2017 Oct; 31(10):2271-2273. PubMed ID: 28751768
[No Abstract] [Full Text] [Related]
8. Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia.
Chonabayashi K; Hishizawa M; Matsui M; Kondo T; Ohno T; Ishikawa T; Takaori-Kondo A
Ann Hematol; 2014 Mar; 93(3):535-7. PubMed ID: 23873282
[No Abstract] [Full Text] [Related]
9. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
[TBL] [Abstract][Full Text] [Related]
10. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
11. ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML.
Spitzer B; Dela Cruz FS; Ibanez Sanchez GD; Zhang Y; Xiao W; Benayed R; Markova A; Rodriguez-Sanchez MI; Bouvier N; Roshal M; Kung AL; Shukla N
Blood Adv; 2021 Apr; 5(7):1899-1902. PubMed ID: 33792628
[TBL] [Abstract][Full Text] [Related]
12. ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant.
Falchi L; Mehrotra M; Newberry KJ; Lyle LM; Lu G; Patel KP; Luthra R; Popat U; Verstovsek S
Leukemia; 2014 Oct; 28(10):2090-2. PubMed ID: 24854988
[No Abstract] [Full Text] [Related]
13. Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.
Chao AK; Meyer JA; Lee AG; Hecht A; Tarver T; Van Ziffle J; Koegel AK; Golden C; Braun BS; Sweet-Cordero EA; Smith CC; Dvorak CC; Loh ML; Stieglitz E
Leukemia; 2020 Feb; 34(2):662-666. PubMed ID: 31511612
[No Abstract] [Full Text] [Related]
14. Two myeloid leukemia cases with rare
Zhang H; Paliga A; Hobbs E; Moore S; Olson S; Long N; Dao KT; Tyner JW
Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30559310
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.
Xuan L; Wang Y; Huang F; Fan Z; Xu Y; Sun J; Xu N; Deng L; Li X; Liang X; Luo X; Shi P; Liu H; Wang Z; Jiang L; Yu C; Zhou X; Lin R; Chen Y; Tu S; Huang X; Liu Q
Lancet Oncol; 2020 Sep; 21(9):1201-1212. PubMed ID: 32791048
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group.
Shomali W; Colucci P; George TI; Kiladjian JJ; Langford C; Patel JL; Reiter A; Vannucchi AM; Gotlib J
Leukemia; 2023 May; 37(5):981-987. PubMed ID: 37076693
[No Abstract] [Full Text] [Related]
17. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.
Lee BH; Williams IR; Anastasiadou E; Boulton CL; Joseph SW; Amaral SM; Curley DP; Duclos N; Huntly BJ; Fabbro D; Griffin JD; Gilliland DG
Oncogene; 2005 Nov; 24(53):7882-92. PubMed ID: 16116483
[TBL] [Abstract][Full Text] [Related]
18. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
Walz C; Erben P; Ritter M; Bloor A; Metzgeroth G; Telford N; Haferlach C; Haferlach T; Gesk S; Score J; Hofmann WK; Hochhaus A; Cross NC; Reiter A
Blood; 2011 Aug; 118(8):2239-42. PubMed ID: 21705501
[TBL] [Abstract][Full Text] [Related]
19. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
